• Teva Page Title

Teva Announces Tentative Approval of Generic Lipitor®

JERUSALEM, Dec 01, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that
the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug
Application (ANDA) for Atorvastatin Calcium Tablets, the generic version of Pfizer's Lipitor®. Annual sales of Lipitor® were
approximately $7.8 billion in the United States as of September 2011, based on IMS sales data. Teva anticipates launching
this product at the end of Ranbaxy's 180-day exclusivity period in May 2012. A portion of the profits from Ranbaxy's sales